Abstract
Background: Brigatinib has demonstrated its efficacy as first-line therapy and in further lines for ALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data in Latin America are scarce. Methods: From January 2018 to March 2020, 46 patients with advanced ALK-positive NSCLC received brigatinib as second or further line of therapy in Mexico and Colombia. The primary end point was progression-free survival (PFS); secondary end point was time to treatment discontinuation (TTD). Results: At a median follow-up of 9.3 months, the median PFS was 15.2 months (95% CI: 11.6-18.8), and TTD was 18.46 months (95% CI: 9.54-27.38). The estimated overall survival at 12 months was 80%. Safety profile was consistent with previously published data. Conclusion: Brigatinib is an effective treatment for previously treated ALK-positive NSCLC patients in a real-world setting.
Keywords:
anaplastic lymphoma kinase; brigatinib; ceritinib; crizotinib; early access; lung cancer; non-small cell lung cancer; real-world evidence.
MeSH terms
-
Anaplastic Lymphoma Kinase / antagonists & inhibitors*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / metabolism*
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Colombia
-
Hispanic or Latino
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / metabolism*
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Mexico
-
Molecular Targeted Therapy*
-
Organophosphorus Compounds / administration & dosage
-
Organophosphorus Compounds / adverse effects
-
Organophosphorus Compounds / therapeutic use*
-
Prognosis
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Treatment Outcome
Substances
-
Organophosphorus Compounds
-
Protein Kinase Inhibitors
-
Pyrimidines
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
brigatinib